Previous Article | Next Article 
Journal of Clinical Microbiology, October 1999, p. 3316-3322, Vol. 37, No. 10
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Detection of Multiple Human Papillomavirus Types in Condylomata
Acuminata Lesions from Otherwise Healthy and Immunosuppressed
Patients
Darron R.
Brown,1,2,*
Jill M.
Schroeder,1
Janine T.
Bryan,2
Mark H.
Stoler,3 and
Kenneth
H.
Fife1,2,4
Departments of
Medicine,1 Microbiology and
Immunology,2 and
Pathology,4 Indiana University
School of Medicine, Indianapolis, Indiana, and Department of
Pathology, University of Virginia Health Sciences Center,
Charlottesville, Virginia3
Received 11 January 1999/Returned for modification 16 April
1999/Accepted 24 June 1999
 |
ABSTRACT |
Condylomata acuminata, or genital warts, are proliferative lesions
of genital epithelium caused by human papillomavirus (HPV) infection.
HPV types 6 and 11 are most often detected in these lesions. Genital
lesions consistent with exophytic condylomata acuminata were removed by
excision biopsy from 65 patients, 41 of whom were otherwise healthy
individuals (control group) and 24 of whom had conditions known to
cause immunosuppression. Histologically, the majority of the lesions
were typical condylomata acuminata. Three lesions removed from
immunosuppressed individuals also contained foci of moderate to severe
dysplasia (intraepithelial neoplasia grade II/III). A recently
developed PCR and reverse blot strip assay was used to determine the
specific HPV types present in the genital lesions. With a set of
oligonucleotide primers based on the same primer binding regions used
for the MY09 and MY11 primer pair, this PCR assay detects the presence
of 27 HPV types known to infect the genital tract. All but two
condylomata acuminata contained either HPV type 6 or 11. The
predominant type in the lesions from control patients was HPV 6, while
lesions from immunosuppressed types most often contained HPV 11. Condylomata acuminata from immunosuppressed patients contained
significantly more overall HPV types than lesions from the control
group. HPV types associated with an increased risk of dysplasia
(high-risk types) were detected in 42 (64.6%) of the total of 65 specimens; 18 (43.9%) specimens were detected in the 41 otherwise
healthy individuals, and 24 (100%) specimens were detected in the 24 immunosuppressed patients. HPV 16 was the most common high-risk type
detected, found in 21 of 65 (32.3%) specimens. After HPV types 6 and
11, HPV types 53 and 54 were the most frequently detected low-risk HPV
types. This study demonstrates that a high percentage of condylomata
acuminata lesions contain multiple HPV types, including types
associated with a high risk of dysplastic abnormalities. Further
studies are needed to determine the influence these additional HPV
types have on the epidemiology of genital tract HPV infections and the natural history of condylomata acuminata, especially in
immunosuppressed patients.
 |
INTRODUCTION |
Approximately one-third of the 90 known human papillomavirus (HPV) types regularly infect the genital
tract, causing a range of manifestations from asymptomatic, latent
infection to the typical exophytic cauliflower-like growths known as
condylomata acuminata to dysplasia and invasive carcinoma of the
cervix. Nearly all condylomata acuminata contain HPV type 6 or 11 (4, 9). Using relatively insensitive methods such as dot
blot hybridization or Southern blot analysis, additional types have
occasionally been detected in genital warts, including HPV types
associated with a high risk of dysplasia, such as HPV 16 (1, 2,
14, 17, 18). In a previous study, we analyzed biopsy samples of exophytic condylomata acuminata lesions for HPV DNA by using the hybrid
capture assay. Some of the patients in the study had conditions known
to depress cell-mediated immunity, such as infection with the human
immunodeficiency virus (HIV) or iatrogenic immunosuppression following
organ transplantation (3, 5). High-risk HPV types were
detected in 55% of the lesions from immunosuppressed individuals but
in only 17% of lesions from otherwise healthy patients. In another
study, we demonstrated that condylomata acuminata removed from
two immunosuppressed patients contained dysplastic abnormalities (8). High-risk genital HPV types were detected in both of
these specimens. It is therefore likely that the natural history of genital warts in immunosuppressed individuals is altered by infection with high-risk HPV types.
The exact distribution of specific HPV types in condylomata acuminata
is not known, but few studies have used highly sensitive methods such
as PCR. Genital lesions consistent with exophytic condylomata acuminata
were removed by excision biopsy from 65 patients, 41 of whom were
otherwise healthy individuals and 24 of whom had conditions known to
cause immunosuppression. Using a recently developed PCR and reverse
blot strip assay, the condylomata acuminata lesions were analyzed for
the presence of HPV. The PCR assay is a modification of a previously
described PCR and reverse blot strip assay with amplimers generated
with the MY09 and MY11 primer pair (10, 11, 15).
 |
MATERIALS AND METHODS |
Patient populations and excision biopsy.
Patients were
evaluated for the presence of condylomata acuminata in a sexually
transmitted disease clinic, a hospital-based gynecology outpatient
clinic, a hospital-based surgical outpatient clinic, or the Indiana
University Transplantation Service. Biopsy was performed if patients
had genital lesions consistent with condylomata acuminata of the
external genitalia or perianal area. All patients provided informed
consent for the excision biopsy procedure. The protocol for biopsy was
approved by the Institutional Review Board at the Indiana University
School of Medicine. Biopsies of typical exophytic condylomata acuminata
were performed on 65 patients as previously described (5).
Twenty-two of these patients were included in the original analysis of
HPV types in condylomata acuminata performed by hybrid capture (5,
8). Forty-one patients, including 10 males, 23 nonpregnant
females, and 8 pregnant females had no known immunosuppressive
condition and are referred to as the control group of patients in the
present study. Twenty-four patients were immunosuppressed: 8 were organ
transplant recipients and 16 were infected with HIV.
Biopsy specimens were held in normal saline until processing occurred,
which was generally within 2 h. A portion of each sample was
processed for histological analysis, which was performed by one
pathologist (M.S.). The remainder of each specimen was frozen in liquid
nitrogen, and DNA was extracted as previously described (5).
DNA was quantified by spectrophotometry. The presence of
high-molecular-weight DNA was established by agarose gel
electrophoresis followed by staining with ethidium bromide. The yields
from tissue samples ranged from approximately 20 to 50 µg of DNA.
PCR assay.
A PCR and reverse blot strip assay with
degenerate primers for amplifying a conserved region of the L1 open
reading frame has been previously described (11). The assay
used in the present study has been modified by developing a set of
oligonucleotide primer pools, called PGMY09 and PGMY11 (10),
based on the same primer binding regions used for the MY09 and MY11
consensus primer PCR assay (15). A set of five upstream
oligonucleotides comprising the PGMY11 primer pool was designed as well
as a set of nine downstream primers comprising the PGMY09 primer pool
(10).
This PCR assay was used to detect 27 HPV types known to infect the
genital tract in DNA purified from 65 exophytic condylomata
acuminata
lesions. Each DNA sample was used in a PCR assay containing
the
consensus primer pair PGMY09 and PGMY11 (
10). The HPV types
detected in the assay are types 6, 11, 16, 18, 26, 31, 33, 35,
39, 40, 42, 45, 51-59, 66, 68, MM4, 83 (formerly designated MM7
;[
7;]), MM8, and MM9. To determine specimen adequacy,
the GH20/PC04
human

-globin target was coamplified with HPV
sequences. Each
primer was labeled with a 5' biotin molecule. For each
condylomata
acuminata lesion, an individual PCR was performed to
potentially
amplify any of the 27 HPV types in the immobilized probe
array.
Each amplification contained 10 mM Tris-HCl (pH 8.5), 50 mM KCl,
4 mM MgCl
2, a 200 µM concentration (each) of dCTP, dGTP,
and dATP,
600 µM dUTP, 7.5 U of AmpliTaq Gold (Perkin-Elmer, Foster
City,
Calif.), 2.5 pmol (each) of the

-globin amplification primers
BPC04 and BGH20, and 5 to 10 µl (approximately 500 ng) of template
DNA. For eventual inclusion of uracil-
N-glycosylase to
prevent
product carryover, dTTP was replaced with dUTP. It has been
determined
that the dUTP concentration must be increased threefold
relative
to the other deoxynucleoside triphosphates for efficient
strand
incorporation by a DNA polymerase (
11). Reactions
were amplified
in a Perkin-Elmer TC9600 thermal cycler by using the
following
profile: 95°C for 9 min (AmpliTaq Gold activation), 40 cycles
of 95°C for 1 min (denaturation), 55°C for 1 min
(annealing),
72°C for 1 min (extension), 72°C for 5 min (final
extension),
and a 15°C hold step. A known positive specimen and a
negative
(no DNA) specimen were included in each assay as
controls.
The general principle of using immobilized probe hybridization has been
described elsewhere (
11). The HPV-immobilized probe
array
contains 29 probe lines plus one reference ink line, detecting
27 individual HPV genotypes and two concentrations of the

-globin
control probe (
11). Bovine serum albumin-conjugated probes
for
each HPV type are deposited in a single line for each of the HPV
types. The high- and low-risk HPV types are visually separated
by the

-globin control lines, such that all types between the
reference and

-globin control lines are associated with high
cancer risk and all
types beyond the control lines are associated
with low cancer risk.
Hybridization and detection of hybridized
PCR products to immobilized
probes were performed as previously
described (
11).
Quantitative analysis of PCR products.
To determine the
relative abundance of different HPV types in the lesions, developed
strips were photographed at a standard magnification with an A2000
digital imaging system (Alpha Innotech, San Leandro, Calif.). The image
of the group of strips was scanned by using the one-dimensional
multiple-lane-scanning module of the Alphaease software that is an
integrated component of the imaging system. The measured density of
each band (peak height) was used as the basis of a semiquantitative,
5-point (1 through 5) scoring system for positive bands. The low- and
high-concentration
-globin bands served as reference points for this
scoring system. The low positive
-globin band was assigned a value
of 2, and the high positive band was assigned a value of 4. Bands that
were clearly visible with sharp margins extending the full width of the
strip but with a peak height that was less than that of the low
positive band were assigned a value of 1, while bands with a height
greater than the high positive band were given a value of 5. The other
values were interpolated between the control values.
To verify that this simple quantitative method correlated with the
viral copy number in the lesions, cloned HPV 16 DNA was
added to 500 ng
of HPV-free human DNA at 10-fold dilutions, beginning
at the equivalent
of one viral copy per cell and ending at the
equivalent of
10
7 viral copies per cell. The PCR and reverse blot strip
assay were
then performed as for the patient samples. A known positive
specimen,
a negative (no DNA) specimen, and a viral DNA-free human
sample
were included in the assay as controls. Quantitative analysis
of
PCR products was then performed as described
above.
 |
RESULTS |
Histologic analysis of biopsies.
The majority of lesions were
histologically condylomata acuminata without any unusual features. The
sections prepared from these biopsies did not contain evidence of fused
lesions potentially caused by independent HPV types. There were three
cases of moderate to severe dysplasia (intraepithelial neoplasia grade
II/III). All three of these lesions were removed from immunosuppressed individuals: two from female transplant recipients (patients 45 and 46)
and the other from an HIV-infected male (patient 57).
Detection of specific HPV types in condylomata acuminata
lesions.
Results of the PCR assay are summarized in Tables
1 and
2. A representative assay
is shown in Fig. 1. Amplification of the control DNA (
-globin) was successful in all 65 condylomata acuminata lesions. As expected, HPV DNA was detected in all specimens. There were
no apparent differences between otherwise healthy adults and pregnant
women, so they were combined (control group) for the analysis of HPV
types in the lesions. Condylomata acuminata from the control group
contained a mean of 2.1 HPV types per specimen, compared to 4.2 HPV
types per specimen from immunosuppressed patients (P < 0.0001, unpaired t test). For high-risk HPV types only,
specimens from the control group contained a mean of 0.8 HPV types per
specimen, compared to 2.3 HPV types per specimen from immunosuppressed
patients (P < 0.0001, unpaired t test).
Overall, HPV types associated with an increased risk of dysplasia were
detected in 46 of 65 (61.5%) specimens. High-risk HPV types were
detected in specimens from 22 of 41 (53.7%) control patients and in
all 24 (100%) specimens from immunosuppressed patients (P < 0.0001, Fisher's exact test).

View larger version (84K):
[in this window]
[in a new window]
|
FIG. 1.
A representative PCR and reverse blot assay was
performed on condylomata acuminata specimens from 15 patients. The
numbers at the top of the figure represent the patients identified in
Tables 1 and 2. Shown on the left side of the figure is a template
identifying the probe specific for each HPV type in the assay, as well
as the -globin controls.
|
|
The overall type distribution for condylomata acuminata lesions is
shown in Fig.
2. HPV type 6 or 11 was
detected in 63 of
65 (96.9%) specimens. All but two
specimens (both from immunosuppressed
patients) contained either
HPV 6 (44 [67.7%] specimens) or HPV
11 (30 [46.2%] specimens).
All specimens from control patients
contained either HPV 6 (37 of 41 [90.2%]) or HPV 11 (13 of 41
[31.7%]), including 9 (22%)
specimens from 41 patients that contained
both HPV types 6 and 11. In
contrast to specimens from control
patients, specimens from
immunosuppressed patients contained HPV
6 in only 7 of 24 (29.2%)
specimens and HPV 11 in 17 of 24 (70.8%)
specimens. Both HPV
types 6 and 11 were detected in 2 of 24 (8.3%)
specimens from
immunosuppressed patients. The difference in detection
of HPV type 6 or
11 between the two patient groups was determined
to be significant
(
P = 0.0002) by a two-sided Fisher's exact test.
Specimens with no detectable HPV other than HPV type 6 or 11 were
common in control patients (18 of 41 [43.9%]), but no specimen
from
immunosuppressed patients contained only HPV type 6 or 11
(
P < 0.0001, Fisher's exact test).

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 2.
Bar graph illustrating the type distribution of HPV
types in condylomata acuminata lesions. Bars indicate the percentages
of lesions from control and immunosuppressed patients containing
particular HPV types.
|
|
Other low-risk types in addition to HPV types 6 and 11 were commonly
detected in specimens from immunosuppressed patients
but were uncommon
in those from control patients. For all specimens,
HPV types 53 and 54 were the most frequently detected low-risk
HPV types after HPV types 6 and 11. HPV 53 was especially common
in lesions removed from
immunosuppressed individuals, being detected
in 6 of 24 (25%)
specimens but in none of the 41 specimens from
control patients
(
P = 0.002, Fisher's exact test). HPV types 42,
54, and MM8 also appeared to be more prevalent in lesions from
immunosuppressed
patients.
For high-risk types, HPV 16 was the most common type detected, being
present in 21 of 65 (32.3%) specimens. HPV 16 was especially
prevalent
in specimens from organ transplant recipients, being
detected in five
of eight (62.5%) specimens. After HPV 16, the
next most frequently
detected high-risk type was HPV 59, present
in 6 of 24 (25%) specimens
from immunosuppressed patients but
in no specimen from control
patients. HPV 18 was detected in 6
of 41 (14.6%) specimens from
control patients and in only 2 of
24 (8.3%) specimens from
immunosuppressed patients. HPV 55 was
detected in 6 of 16 (37.5%)
specimens from HIV-positive patients
but less often in specimens from
control patients or transplant
recipients.
Several HPV types were detected exclusively in lesions from
immunosuppressed patients. These included both low-risk types
(HPV
types 53 and 57) and high-risk types (HPV types 59, 68, and
MM4). In
contrast, no HPV types were detected exclusively in specimens
from
control patients. HPV types 33, 35, and 58 (high risk) and
HPV 40 (low
risk) were not detected in any
specimen.
Quantitative analysis of PCR products.
Signals generated in
the PCR and reverse blot strip assay of the HPV 16 dilutions were
quantified by scanning densitometry (Fig.
3). At one viral copy per cell, HPV 16 was detected at a signal strength of 5. Dilutions of viral DNA up to
100 viral copies per cell also generated signals of 5, indicating that
HPV types in amounts greater than a single copy would not be accurately quantified (data not shown). At 10
4 viral copies per
cell, a signal strength of 1 was generated. This amount of viral DNA
corresponded to approximately 30 genomic viral copies in the 500-ng
human DNA sample. At 10
5 viral copies per cell, or the
equivalent of three genomic viral copies in the 500-ng human DNA
sample, no signal was generated.

View larger version (97K):
[in this window]
[in a new window]
|
FIG. 3.
Quantitative analysis of PCR products by using cloned
HPV 16 DNA added to HPV-free human DNA. Lane 1, PCR containing no
template; lane 2, PCR containing 500 ng of DNA from a clinical specimen
known to contain six different HPV types. The remaining lanes contain
strips hybridized with serial 10-fold dilutions of cloned HPV 16 DNA
made in 500 ng of HPV-negative human DNA and subjected to PCR. Lane 3, the equivalent of 100 viral copies per cell; lane 4, 10 1 viral copies per cell; lane 5, 10 2
viral copies per cell; lane 6, 10 3 viral copies per cell;
lane 7, 10 4 viral copies per cell; lane 8, 10 5 viral copies per cell; lane 9, 10 6
viral copies per cell; lane 10, 10 7 viral copies per
cell. The upper arrow on the right side of the figure shows the
position of the HPV 16 band, the first HPV type represented on these
strips. The two bands just below the center of the strips are the high-
and low-quantity -globin amplification controls, respectively.
|
|
Signals generated in the PCR and reverse blot strip assay of patient
samples were quantified by scanning densitometry. Signals
from 1 to 5 were obtained. As indicated in Table
1, HPV types
6 and 11 were
generally detected in abundance (4 or 5) in condylomata
acuminata
lesions from all patients. Many specimens from all patient
groups
contained high levels of HPV types in addition to HPV type
6 or 11. For
low-risk types other than HPV type 6 or 11, amplimers
at level 5 were
detected in 3 of 41 (7.3%) specimens from control
patients, compared
to 6 of 24 (25%) specimens from immunosuppressed
patients
(
P = 0.066, Fisher's exact test). High-risk types were
detected in abundance (5 on a scale of 1 to 5) in 7 of 41 (17.1%)
specimens from control patients, compared to 14 of 24 (58.3%)
specimens from immunosuppressed patients (
P = 0.001,
Fisher's
exact
test).
 |
DISCUSSION |
This study demonstrates that most condylomata acuminata lesions
contain multiple HPV types, including types associated with dysplastic
epithelial abnormalities. Using PCR, high-risk HPV types were detected
in more than half of the condylomata acuminata lesions from otherwise
healthy individuals and in 100% of the specimens from immunosuppressed
patients. High-risk HPV types that were especially common in specimens
from immunosuppressed patients included HPV types 16, 55, and 59.
In addition, the distribution of low-risk HPV types differed between
specimens from the healthy patient groups and those from the
immunosuppressed patients. HPV 6 is reported to be the most commonly
detected type in condylomata acuminata lesions (4, 9). This
was the case in the present study in the specimens from control
patients. Unexpectedly, the distribution of HPV 6 and HPV 11 in
specimens from immunocompetent and immunosuppressed patients differed
markedly. In specimens from control patients, HPV 6 was detected more
often than HPV 11; this trend was reversed in specimens from
immunosuppressed patients. This statistically significant finding is
not easily explained, as these two HPV types are closely related. Other
low-risk types were commonly detected in specimens from
immunosuppressed patients. For example, HPV 53 was commonly detected in
specimens from HIV-infected patients (5 of 16 lesions).
It is well established that HPV types 6 and 11 are the major etiologic
agents of condylomata acuminata lesions. The significance of additional
HPV types in these lesions has not been established, although foci of
high-grade dysplasia have been identified in lesions removed from
immunosuppressed patients (8). The presence of multiple HPV
types in a large percentage of condylomata acuminata lesions suggests
that many individuals acquire additional HPV types at the time of
infection with HPV type 6 or 11. High-risk HPV types and additional
low-risk HPV types may be retained at very low quantities in
condylomata acuminata lesions in healthy people but may begin to
replicate if immunosuppression occurs. While reactivation of latent
infection appears to be the likely mechanism for detection of high-risk
and additional low-risk types in these lesions, it is also possible
that some patients have a large number of sexual partners and are
exposed to multiple HPV types during their lives. Additional HPV types
could therefore be accumulated over time.
Another possibility is that low-risk types are more difficult for the
cellular immune system of genital epithelium to control than are
high-risk types. This hypothesis could explain the observation that
low-risk types were found more often in nearly all condylomata acuminata lesions, while high-risk HPV types were detected most often
in immunosuppressed patients.
Other studies using less sensitive and less comprehensive HPV detection
methods have shown that more than one HPV type may be present in
condylomata acuminata lesions. Bergeron et al. found evidence of
more than one HPV type in 17% of lesions analyzed by Southern blot
hybridization (2). Wickenden et al. analyzed condylomata
acuminata and cervical cells by a dot hybridization assay for the
presence of HPV (cited in reference 2). They found by using
whole genomic probes that 32% of the DNA contained more than one HPV
type, including HPV types 6, 11, 16, and 18. Langenberg et al. found
evidence of more than one HPV type in 6.3% of condylomata acuminata
samples by the Southern blot method (14). Wilbur et al.
analyzed 180 condylomata acuminata by RNA in situ hybridization
(18). Two cases of coinfection with HPV types 6 and 16 were
found. In contrast to these studies, Beckman et al. analyzed 33 condylomata acuminata by a variety of methods and found no cases
containing more than one HPV type (1).
A few studies have utilized PCR to detect HPV types in genital tract
lesions. Hildesheim et al. identified mixed HPV infections in 43% of
patients with typable HPV detected by consensus primer PCR
(12). The samples analyzed in that study were cervical
lavages and thus were obtained from a large anatomic area, unlike our samples, which were biopsies of external skin containing only abnormal
cells by histology.
A recent study used the degenerate MY09 and MY11 primer pair in a
PCR to amplify the conserved portion of the L1 open reading frame
(16). In that study, 47 condylomata acuminata lesions were
shown to contain a single infection with HPV type 6 or 11 in 45 specimens and a double infection with a high-risk type in only two
cases. No information was given regarding the immune status of the
patient population. Our analysis differs markedly. A possible
explanation is that the PCR assay in our study amplifies and detects
HPV in genital samples with better sensitivity than other assays. The
PCR and reverse blot strip assay employed in our study used different
primer pools than the MY09 and MY11 primer pair used in prior studies.
In addition, prior studies utilized a generic probe for detection
rather than the individual probes used in our study.
The quantitative assay devised for analysis of condylomata acuminata
lesions showed that a wide range of viral copy numbers was present in
the lesions. HPV types 6 and/or 11 were detected in abundance in nearly
all samples (level 4 or 5 in the quantitative assay). Although many
additional HPV types were detected in relatively large quantities, the
amount of HPV type 6 or 11 in most specimens was probably outside the
linear range for quantification in this assay.
Confirmation of multiple HPV types in these lesions by additional tests
would be desirable but difficult with current methods other than PCR.
Methods such as DNA in situ hybridization lack the combination of high
sensitivity, high specificity, and simplicity afforded by PCR. Although
HPV cannot be grown in cell culture, certain HPV types have been
propagated in the athymic mouse xenograft system (13). We
have confirmed the presence of three high-risk HPV types (HPV types 18, 59, and 83) in lesions from three patients (patients 60, 43, and 64, respectively) by producing extracts, infecting human foreskin
fragments, and propagating infectious stocks of these HPVs (6,
7a).
In conclusion, multiple HPV types were detected in most exophytic
condylomata acuminata specimens. HPV types associated with a high risk
of dysplasia were detected frequently. Certain HPV types were detected
only in specimens from immunosuppressed patients. These
immunosuppression-related types include several that are largely
uncharacterized in terms of epidemiology and pathogenesis. Further
studies are needed to determine the influence that multiple HPV type
infections have on the natural history of condylomata acuminata,
especially in immunosuppressed individuals. As patients with conditions
that alter immune functions benefit from new therapies and experience
extended life spans, it is possible that coinfection of genital
epithelium with low- and high-risk HPV types will be manifested as
dysplastic disease.
 |
ACKNOWLEDGMENTS |
This study was funded in part by a cooperative agreement AI31494
from the National Institute of Allergy and Infectious Diseases.
We thank Patti Gravitt and Raymond J. Apple (Roche Molecular
Systems, Inc.) for providing the PCR and reverse blot assay and for
helpful advice.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Infectious Diseases, Indiana University School of Medicine, Emerson
Hall 435, 545 Barnhill Drive, Indianapolis, IN 46202-5124. Phone: (317) 274-8115. Fax: (317) 274-1587. E-mail: darbrow{at}iupui.edu.
 |
REFERENCES |
| 1.
|
Beckmann, A. M.,
K. J. Sherman,
D. Myerson,
J. R. Daling,
J. K. McDougall, and D. A. Galloway.
1991.
Comparative virologic studies of condylomata acuminata reveal a lack of dual infections with human papillomavirus.
J. Infect. Dis.
163:393-396[Medline].
|
| 2.
|
Bergeron, C.,
A. Ferenczy,
K. V. Shah, and Z. Naghashfar.
1987.
Multicentric human papillomavirus infections of the female genital tract: correlation of viral types with abnormal mitotic figures, colposcopic presentation, and location.
Obstet. Gynecol.
69:736-742[Medline].
|
| 3.
|
Brachman, D. G.
1994.
Molecular biology of head and neck cancer.
Semin. Oncol.
21:320-329[Medline].
|
| 4.
|
Brown, D. R.,
J. T. Bryan,
H. Cramer, and K. H. Fife.
1993.
Analysis of human papillomavirus types in exophytic condylomata acuminata by hybrid capture and Southern blot techniques.
J. Clin. Microbiol.
31:2667-2673[Abstract/Free Full Text].
|
| 5.
|
Brown, D. R.,
J. T. Bryan,
H. Cramer,
B. P. Katz,
V. Handy, and K. H. Fife.
1994.
Detection of multiple human papillomavirus types in condylomata acuminata from immunosuppressed patients.
J. Infect. Dis.
170:759-765[Medline].
|
| 6.
|
Brown, D. R.,
T. L. McClowry,
J. T. Bryan,
M. Stoler,
J. M. Schroeder-Diedrich, and K. H. Fife.
1998.
A human papillomavirus related to human papillomavirus MM7/LVX82 produces distinct histological abnormalities in human foreskin implants grown as athymic mouse xenografts.
Virology
249:150-159[Medline].
|
| 7.
|
Brown, D. R.,
T. L. McClowry,
K. Woods, and K. H. Fife.
1999.
Nucleotide sequence and characterization of human papillomavirus type 83, a novel genital papillomavirus.
Virology
260:165-172[Medline].
|
| 7a.
| Brown, D. R., et al. Unpublished observations.
|
| 8.
|
Bryan, J. T.,
M. H. Stoler,
S. K. Tyring,
T. McClowry,
K. H. Fife, and D. R. Brown.
1998.
High-grade dysplasia in genital warts from two patients infected with the human immunodeficiency virus.
J. Med. Virol.
54:69-73[Medline].
|
| 9.
|
Gissmann, L.,
L. Wolnik,
H. Ikenberg,
U. Koldovsky,
H. G. Schnurch, and H. zur Hausen.
1983.
Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers.
Proc. Natl. Acad. Sci. USA
80:560-563[Abstract/Free Full Text].
|
| 10.
| Gravitt, P. E., C. Peyton, T. Alessi, C. Wheeler,
F. Coultee, A. Hildesheim, and R. Apple. Unpublished data.
|
| 11.
|
Gravitt, P. E.,
C. L. Peyton,
R. J. Apple, and C. M. Wheeler.
1998.
Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method.
J. Clin. Microbiol.
36:3020-3027[Abstract/Free Full Text].
|
| 12.
|
Hildesheim, A.,
M. H. Schiffman,
P. E. Gravitt,
A. G. Glass,
C. E. Greer,
T. Zhang,
D. R. Scott,
B. B. Rush,
P. Lawler,
M. E. Sherman,
R. J. Kurman, and M. M. Manos.
1994.
Persistence of type-specific human papillomavirus infection among cytologically normal women.
J. Infect. Dis.
169:235-240[Medline].
|
| 13.
|
Kreider, J. W.,
M. K. Howlett,
N. L. Lill,
G. L. Bartlett,
R. J. Zaino,
T. V. Sedlacek, and R. Mortel.
1986.
In vivo transformation of human skin with human papillomavirus type 11 from condylomata acuminata.
J. Virol.
59:369-376[Abstract/Free Full Text].
|
| 14.
|
Langenberg, A.,
R. Cone,
J. McDougall,
N. Kiviat, and L. Corey.
1993.
Dual infection with human papillomavirus in a population with overt genital condylomas.
J. Am. Acad. Dermatol.
28:434-442[Medline].
|
| 15.
|
Manos, M. M.,
Y. Ting,
D. K. Wright,
A. J. Lewis,
T. R. Broker, and S. M. Wolinsky.
1989.
Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses.
Cancer Cells
7:209-214.
|
| 16.
|
Meyer, T.,
R. Arndt,
E. Christophers,
E. R. Beckmann,
S. Schroder,
L. Gissmann, and E. Stockfleth.
1998.
Association of rare human papillomavirus types with genital premalignant and malignant lesions.
J. Infect. Dis.
178:252-255[Medline].
|
| 17.
|
Nuovo, G. J.,
M. M. Darfler,
C. C. Impraim, and S. E. Bromley.
1991.
Occurrence of multiple types of human papillomavirus in genital tract lesions.
Am. J. Pathol.
138:53-58[Abstract].
|
| 18.
|
Wilbur, D. C.,
R. C. Reichman, and M. H. Stoler.
1988.
Detection of infection by human papillomavirus in genital condylomata. A comparison study using immunocytochemistry and in situ nucleic acid hybridization.
Am. J. Clin. Pathol.
89:505-510[Medline].
|
Journal of Clinical Microbiology, October 1999, p. 3316-3322, Vol. 37, No. 10
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Dee, A, Howell, F, O'Connor, C, Cremin, S, Hunter, K
(2009). Determining the cost of genital warts: a study from Ireland. Sex. Transm. Infect.
85: 402-403
[Abstract]
[Full Text]
-
Hutchinson, D. J., Klein, K. C.
(2008). Human papillomavirus disease and vaccines. Am J Health Syst Pharm
65: 2105-2112
[Abstract]
[Full Text]
-
Wang, H, Qiao, Y L
(2008). Human papillomavirus type-distribution in condylomata acuminata of mainland China: a meta-analysis. Int J STD AIDS
19: 680-684
[Abstract]
[Full Text]
-
Insinga, R. P., Liaw, K.-L., Johnson, L. G., Madeleine, M. M.
(2008). A Systematic Review of the Prevalence and Attribution of Human Papillomavirus Types among Cervical, Vaginal, and Vulvar Precancers and Cancers in the United States. Cancer Epidemiol. Biomarkers Prev.
17: 1611-1622
[Abstract]
[Full Text]
-
Dempsey, A. F., Gebremariam, A., Koutsky, L., Manhart, L.
(2008). Behavior in Early Adolescence and Risk of Human Papillomavirus Infection as a Young Adult: Results From a Population-Based Study. Pediatrics
122: 1-7
[Abstract]
[Full Text]
-
Woodhall, S, Ramsey, T, Cai, C, Crouch, S, Jit, M, Birks, Y, Edmunds, W J, Newton, R, Lacey, C J N
(2008). Estimation of the impact of genital warts on health-related quality of life. Sex. Transm. Infect.
84: 161-166
[Abstract]
[Full Text]
-
Goon, P, Sonnex, C
(2008). Frequently asked questions about genital warts in the genitourinary medicine clinic: an update and review of recent literature. Sex. Transm. Infect.
84: 3-7
[Abstract]
[Full Text]
-
Insinga, R. P., Dasbach, E. J., Elbasha, E. H., Liaw, K.-L., Barr, E.
(2007). Incidence and Duration of Cervical Human Papillomavirus 6, 11, 16, and 18 Infections in Young Women: An Evaluation from Multiple Analytic Perspectives. Cancer Epidemiol. Biomarkers Prev.
16: 709-715
[Abstract]
[Full Text]
-
Silverberg, M. J., Thorsen, P., Lindeberg, H., Ahdieh-Grant, L., Shah, K. V.
(2004). Clinical Course of Recurrent Respiratory Papillomatosis in Danish Children. Arch Otolaryngol Head Neck Surg
130: 711-716
[Abstract]
[Full Text]
-
Levi, J. E., Kleter, B., Quint, W. G. V., Fink, M. C. S., Canto, C. L. M., Matsubara, R., Linhares, I., Segurado, A., Vanderborght, B., Neto, J. E., van Doorn, L.-J.
(2002). High Prevalence of Human Papillomavirus (HPV) Infections and High Frequency of Multiple HPV Genotypes in Human Immunodeficiency Virus-Infected Women in Brazil. J. Clin. Microbiol.
40: 3341-3345
[Abstract]
[Full Text]
-
Emeny, R. T., Wheeler, C. M., Jansen, K. U., Hunt, W. C., Fu, T.-M., Smith, J. F., MacMullen, S., Esser, M. T., Paliard, X.
(2002). Priming of Human Papillomavirus Type 11-Specific Humoral and Cellular Immune Responses in College-Aged Women with a Virus-Like Particle Vaccine. J. Virol.
76: 7832-7842
[Abstract]
[Full Text]